119 related articles for article (PubMed ID: 14998329)
41. Himalayan
Tewari D; Gupta P; Bawari S; Sah AN; Barreca D; Khayatkashani M; Khayat Kashani HR
Plants (Basel); 2021 Aug; 10(8):. PubMed ID: 34451731
[TBL] [Abstract][Full Text] [Related]
42. A Crosstalk between the Cannabinoid Receptors and Nociceptin Receptors in Colitis-Clinical Implications.
Wołyniak M; Małecka-Wojciesko E; Zielińska M; Fabisiak A
J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431153
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
[TBL] [Abstract][Full Text] [Related]
44. Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic.
Severino AL; Shadfar A; Hakimian JK; Crane O; Singh G; Heinzerling K; Walwyn WM
Front Psychiatry; 2018; 9():119. PubMed ID: 29740351
[TBL] [Abstract][Full Text] [Related]
45. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
[TBL] [Abstract][Full Text] [Related]
46. Molecular Pharmacology of δ-Opioid Receptors.
Gendron L; Cahill CM; von Zastrow M; Schiller PW; Pineyro G
Pharmacol Rev; 2016 Jul; 68(3):631-700. PubMed ID: 27343248
[TBL] [Abstract][Full Text] [Related]
47. The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.
Anand JP; Boyer BT; Mosberg HI; Jutkiewicz EM
Psychopharmacology (Berl); 2016 Jul; 233(13):2479-87. PubMed ID: 27117141
[TBL] [Abstract][Full Text] [Related]
48. Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.
Gharavi R; Hedrich W; Wang H; Hassan HE
Pharm Res; 2015 Aug; 32(8):2477-502. PubMed ID: 25972096
[TBL] [Abstract][Full Text] [Related]
49. Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists.
Kumar V; Clark MJ; Traynor JR; Lewis JW; Husbands SM
Bioorg Med Chem; 2014 Aug; 22(15):4067-72. PubMed ID: 24973818
[TBL] [Abstract][Full Text] [Related]
50. Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.
Anand JP; Porter-Barrus VR; Waldschmidt HV; Yeomans L; Pogozheva ID; Traynor JR; Mosberg HI
Biopolymers; 2014 Jan; 102(1):107-14. PubMed ID: 24436042
[TBL] [Abstract][Full Text] [Related]
51. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
52. 14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.
Ananthan S; Saini SK; Dersch CM; Xu H; McGlinchey N; Giuvelis D; Bilsky EJ; Rothman RB
J Med Chem; 2012 Oct; 55(19):8350-63. PubMed ID: 23016952
[TBL] [Abstract][Full Text] [Related]
53. Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.
Anand JP; Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
Chem Biol Drug Des; 2012 Nov; 80(5):763-70. PubMed ID: 22882801
[TBL] [Abstract][Full Text] [Related]
54. Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components.
Ding J; Lemieux C; Chung NN; Schiller PW
Chem Biol Drug Des; 2012 Feb; 79(2):186-93. PubMed ID: 22070627
[TBL] [Abstract][Full Text] [Related]
55. Regulation of male fertility by the opioid system.
Subirán N; Casis L; Irazusta J
Mol Med; 2011; 17(7-8):846-53. PubMed ID: 21431247
[TBL] [Abstract][Full Text] [Related]
56. Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.
Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
J Med Chem; 2009 Dec; 52(23):7724-31. PubMed ID: 19788201
[TBL] [Abstract][Full Text] [Related]
57. The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety.
Yamamoto T; Nair P; Ma SW; Davis P; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ
Bioorg Med Chem; 2009 Oct; 17(20):7337-43. PubMed ID: 19762245
[TBL] [Abstract][Full Text] [Related]
58. Bi- or multifunctional opioid peptide drugs.
Schiller PW
Life Sci; 2010 Apr; 86(15-16):598-603. PubMed ID: 19285088
[TBL] [Abstract][Full Text] [Related]
59. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Balboni G; Onnis V; Congiu C; Zotti M; Sasaki Y; Ambo A; Bryant SD; Jinsmaa Y; Lazarus LH; Trapella C; Salvadori S
J Med Chem; 2006 Sep; 49(18):5610-7. PubMed ID: 16942034
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
